DexCom, Inc. (DXCM)

USD 75.26

(-3.26%)

Market Cap (In USD)

29.39 Billion

Revenue (In USD)

3.62 Billion

Net Income (In USD)

541.5 Million

Avg. Volume

5.47 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
62.34-142.0
PE
-
EPS
-
Beta Value
1.173
ISIN
US2521311074
CUSIP
252131107
CIK
1093557
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Kevin Ronald Sayer
Employee Count
-
Website
https://www.dexcom.com
Ipo Date
2005-04-14
Details
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.